Literature DB >> 7721404

Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects.

M Burnier1, M Hagman, J Nussberger, J Biollaz, C Armagnac, R Brouard, B Weber, H R Brunner.   

Abstract

We investigated the short-term and sustained hormonal and renal effects of angiotensin II (Ang II) receptor blockade in normotensive healthy volunteers. Twenty-four subjects maintained on a fixed sodium diet were randomized to receive for 8 days a placebo or 10 or 50 mg doses of the Ang II antagonist irbesartan (SR 47436, BMS 186295) according to a double-blind, parallel group design. Plasma renin activity, plasma immunoreactive Ang II and aldosterone levels, blood pressure, renal hemodynamics, and urinary electrolyte excretion were measured for 8 hours after the first and eighth administration of each dose of irbesartan or placebo. Ang II receptor blockade with irbesartan induced a dose-dependent compensatory increase in plasma renin activity and plasma angiotensin levels and a significant decrease in plasma aldosterone levels. The compensatory rise in plasma renin activity and Ang II levels was more pronounced on day 8, reflecting a long duration of the blocking effect of irbesartan. Irbesartan induced small changes in blood pressure and did not significantly modify renal blood flow and glomerular filtration rate. However, a significant decrease in filtration fraction was observed during receptor blockade on days 1 and 8. The tubular effects of irbesartan were characterized by a dose-dependent increase in sodium and chloride excretions. Interestingly, the cumulative natriuretic response to Ang II receptor blockade was similar on days 1 and 8, suggesting that in these subjects, renal Ang II receptors are not blocked over 24 hours during repeated administration even though this antagonist has a long duration of action (t1/2 of 15 to 17 hours).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721404     DOI: 10.1161/01.hyp.25.4.602

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

Review 1.  Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.

Authors:  C Csajka; T Buclin; H R Brunner; J Biollaz
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 2.  Irbesartan: an updated review of its use in cardiovascular disorders.

Authors:  A Markham; C M Spencer; B Jarvis
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

Review 3.  Comparative safety and tolerability of angiotensin II receptor antagonists.

Authors:  L Mazzolai; M Burnier
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

Review 4.  Treatment of hypertension in diabetes mellitus.

Authors:  A de La Sierra; L M Ruilope
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

5.  Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension.

Authors:  Wilma Debernardi-Venon; Claudio Barletti; Carlo Alessandria; Alfredo Marzano; M Baronio; Luca Todros; Giorgio Saracco; Alessandro Repici; Mario Rizzetto
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

6.  Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis.

Authors:  N Girgrah; P Liu; J Collier; L Blendis; F Wong
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 7.  Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.

Authors:  J C Gillis; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 8.  Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Authors:  Katherine F Croom; Monique P Curran; Karen L Goa; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Hemodynamic effect of angiotensin II receptor blockade in postmenopausal women on a high-sodium diet: A double-blind, randomized, placebo-controlled study.

Authors:  Antoinette Pechère-Bertschi; Marc Maillard; Paul Bischof; Marc Fathi; Michel Burnier
Journal:  Curr Ther Res Clin Exp       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.